• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于定量健康个体和癌症患者血清中细胞角蛋白8和18片段的新型免疫放射分析和酶联免疫吸附测定。

A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients.

作者信息

Silén A, Wiklund B, Andersson E L, Nilsson S

机构信息

AB IDL ImmunoDevelopLab, Borlänge, Sweden.

出版信息

Scand J Clin Lab Invest. 1995 Apr;55(2):153-61. doi: 10.3109/00365519509089608.

DOI:10.3109/00365519509089608
PMID:7545308
Abstract

Cytokeratins 8 and 18 are most frequently co-expressed in simple epithelia and carcinomas. Fragments of these cytokeratins are released into the systemic circulation where they can be quantified and utilized as tumour markers. The present paper reports on a solid-phase sandwich monoclonal immunoassay, considered "epithelial tissue-specific", which recognizes fragments of human cytokeratins 8 and 18 of different sizes (10-50 kD). The evaluated ELISA and IRMA assays exhibited a detection limit of 0.1 microgram 1-1 and characteristically demonstrated a within-assay coefficient of variation (CV) of 1-4% and a between-assay CV of 3-5%. The long-term (300 days) repeatability of lyophilized samples tested in the assay was estimated to have a less than 10% CV. Of apparently healthy individuals, 95% were found to have serum concentrations of less than 0.95 micrograms 1-1. A highly significant difference was found between apparently healthy individuals and pancreatic cancer patients. Patients with metastatic disease showed a sensitivity of 93% and those with local disease 83%, at 95% specificity. This TPAcyk assay revealed good correlation (0.98) with the TPS assay detecting the specific M3 epitope of the tissue polypeptide antigen. The correlation with the long established polyclonal assay of tissue polypeptide antigen (TPA) was estimated to be 0.9.

摘要

细胞角蛋白8和18最常共同表达于单层上皮和癌组织中。这些细胞角蛋白的片段会释放到体循环中,在那里它们可以被定量并用作肿瘤标志物。本文报道了一种被认为是“上皮组织特异性”的固相夹心单克隆免疫测定法,该方法可识别不同大小(10 - 50 kD)的人细胞角蛋白8和18的片段。所评估的ELISA和IRMA测定法的检测限为0.1微克/升,批内变异系数(CV)为1 - 4%,批间CV为3 - 5%。在该测定法中测试的冻干样品的长期(300天)重复性估计CV小于10%。在明显健康的个体中,发现95%的人血清浓度低于0.95微克/升。在明显健康的个体和胰腺癌患者之间发现了高度显著的差异。在95%的特异性下,转移性疾病患者的敏感性为93%,局部疾病患者为83%。这种TPAcyk测定法与检测组织多肽抗原特异性M3表位的TPS测定法显示出良好的相关性(0.98)。与长期建立的组织多肽抗原(TPA)多克隆测定法的相关性估计为0.9。

相似文献

1
A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients.一种用于定量健康个体和癌症患者血清中细胞角蛋白8和18片段的新型免疫放射分析和酶联免疫吸附测定。
Scand J Clin Lab Invest. 1995 Apr;55(2):153-61. doi: 10.3109/00365519509089608.
2
Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast cancer. Evaluation in serum and tumour tissue.原发性乳腺癌中的组织多肽抗原和组织多肽特异性抗原。血清和肿瘤组织中的评估。
Eur J Clin Chem Clin Biochem. 1994 Oct;32(10):779-87. doi: 10.1515/cclm.1994.32.10.779.
3
The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19.肿瘤标志物TPA、TPS、TPACYK和CYFRA 21-1与角蛋白8、18和19的反应不同。
Int J Biol Markers. 1994 Apr-Jun;9(2):70-4. doi: 10.1177/172460089400900202.
4
High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients.鳞状细胞肺癌患者血清中细胞角蛋白19片段水平较高,但未检测到细胞角蛋白1、2、10/11、14或丝聚合蛋白。
Tumour Biol. 2001 Jan-Feb;22(1):19-26. doi: 10.1159/000030151.
5
Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer.细胞角蛋白19片段21-1、组织多肽抗原免疫放射分析及组织多肽抗原乳胶免疫比浊法在膀胱癌中的临床意义
Anticancer Res. 1996 Nov-Dec;16(6B):3793-8.
6
Development of a new Prolifigen TPA IRMA assay using monoclonal anti-cytokeratin antibodies.使用单克隆抗细胞角蛋白抗体开发一种新的增殖素组织纤溶酶原激活剂免疫放射分析方法。
Int J Biol Markers. 1995 Jul-Sep;10(3):166-73. doi: 10.1177/172460089501000307.
7
[Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].卵巢癌中的细胞角蛋白肿瘤标志物:组织多肽特异性抗原(TPS)和M3/M21
Wien Klin Wochenschr. 1998 Oct 2;110(18):635-41.
8
Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen.一种基于单克隆抗体的新型组织多肽抗原免疫测定法的临床概况。
Int J Biol Markers. 1994 Oct-Dec;9(4):231-8. doi: 10.1177/172460089400900405.
9
Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.宫颈癌患者治疗前血清细胞角蛋白19片段、组织多肽抗原及鳞状细胞癌抗原水平的临床价值
Cancer. 1995 Sep 1;76(5):807-13. doi: 10.1002/1097-0142(19950901)76:5<807::aid-cncr2820760515>3.0.co;2-m.
10
Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.支气管灌洗中细胞角蛋白肿瘤标志物水平在肺癌诊断中的应用
Chest. 1996 Jan;109(1):104-8. doi: 10.1378/chest.109.1.104.

引用本文的文献

1
Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.血清M30和M65水平在转移性胰腺腺癌中的临床意义
Tumour Biol. 2013 Dec;34(6):3529-36. doi: 10.1007/s13277-013-0931-8. Epub 2013 Jun 21.
2
A list of candidate cancer biomarkers for targeted proteomics.一份用于靶向蛋白质组学的候选癌症生物标志物清单。
Biomark Insights. 2007 Feb 7;1:1-48.
3
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
用于评估靶向X连锁凋亡抑制蛋白XIAP的反义化合物(AEG35156)临床疗效的药效学生物标志物的方法验证和初步鉴定。
Br J Cancer. 2006 Jul 3;95(1):42-8. doi: 10.1038/sj.bjc.6603220.